ID   SHIP1_HUMAN             Reviewed;        1189 AA.
AC   Q92835; O00145; Q13544; Q13545; Q6P5A4; Q92656; Q9UE80;
DT   11-SEP-2007, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 2.
DT   10-MAY-2017, entry version 141.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1;
DE            EC=3.1.3.86;
DE   AltName: Full=Inositol polyphosphate-5-phosphatase of 145 kDa;
DE            Short=SIP-145;
DE   AltName: Full=SH2 domain-containing inositol 5'-phosphatase 1;
DE            Short=SH2 domain-containing inositol phosphatase 1;
DE            Short=SHIP-1;
DE   AltName: Full=p150Ship;
DE            Short=hp51CN;
GN   Name=INPP5D; Synonyms=SHIP, SHIP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ENZYME ACTIVITY, TISSUE
RP   SPECIFICITY, AND VARIANT TYR-1169.
RX   PubMed=8769125; DOI=10.1006/bbrc.1996.1161;
RA   Drayer A.L., Pesesse X., De Smedt F., Woscholski R., Parker P.,
RA   Erneux C.;
RT   "Cloning and expression of a human placenta inositol 1,3,4,5-
RT   tetrakisphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-
RT   phosphatase.";
RL   Biochem. Biophys. Res. Commun. 225:243-249(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND
RP   INTERACTION WITH SHC1.
RX   PubMed=8874179;
RA   Ware M.D., Rosten P., Damen J.E., Liu L., Humphries R.K., Krystal G.;
RT   "Cloning and characterization of human SHIP, the 145-kD inositol 5-
RT   phosphatase that associates with SHC after cytokine stimulation.";
RL   Blood 88:2833-2840(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1-1139 (ISOFORM 1), ENZYME ACTIVITY, AND INTERACTION WITH GRB2.
RC   TISSUE=Lung;
RX   PubMed=8723348; DOI=10.1016/S0960-9822(02)00511-0;
RA   Kavanaugh W.M., Pot D.A., Chin S.M., Deuter-Reinhard M.,
RA   Jefferson A.B., Norris F.A., Masiarz F.R., Cousens L.S., Majerus P.W.,
RA   Williams L.T.;
RT   "Multiple forms of an inositol polyphosphate 5-phosphatase form
RT   signaling complexes with Shc and Grb2.";
RL   Curr. Biol. 6:438-445(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=9058707;
RA   Geier S.J., Algate P.A., Carlberg K., Flowers D., Friedman C.,
RA   Trask B., Rohrschneider L.R.;
RT   "The human SHIP gene is differentially expressed in cell lineages of
RT   the bone marrow and blood.";
RL   Blood 89:1876-1885(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   PHOSPHORYLATION, AND INTERACTION WITH GRB2.
RX   PubMed=9108392;
RA   Odai H., Sasaki K., Iwamatsu A., Nakamoto T., Ueno H., Yamagata T.,
RA   Mitani K., Yazaki Y., Hirai H.;
RT   "Purification and molecular cloning of SH2- and SH3-containing
RT   inositol polyphosphate-5-phosphatase, which is involved in the
RT   signaling pathway of granulocyte-macrophage colony-stimulating factor,
RT   erythropoietin, and Bcr-Abl.";
RL   Blood 89:2745-2756(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   TYR-1169.
RC   TISSUE=B-cell, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH SLAMF1.
RX   PubMed=10229804;
RA   Mikhalap S.V., Shlapatska L.M., Berdova A.G., Law C.L., Clark E.A.,
RA   Sidorenko S.P.;
RT   "CDw150 associates with src-homology 2-containing inositol phosphatase
RT   and modulates CD95-mediated apoptosis.";
RL   J. Immunol. 162:5719-5727(1999).
RN   [8]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH DOK1.
RX   PubMed=10822173; DOI=10.1016/S0898-6568(00)00073-5;
RA   Dunant N.M., Wisniewski D., Strife A., Clarkson B., Resh M.D.;
RT   "The phosphatidylinositol polyphosphate 5-phosphatase SHIP1 associates
RT   with the dok1 phosphoprotein in bcr-Abl transformed cells.";
RL   Cell. Signal. 12:317-326(2000).
RN   [9]
RP   FUNCTION.
RX   PubMed=12421919; DOI=10.4049/jimmunol.169.10.5441;
RA   Freeburn R.W., Wright K.L., Burgess S.J., Astoul E., Cantrell D.A.,
RA   Ward S.G.;
RT   "Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-
RT   trisphosphate metabolism in T lymphocytes and can regulate novel
RT   phosphoinositide 3-kinase effectors.";
RL   J. Immunol. 169:5441-5450(2002).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-915, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [11]
RP   FUNCTION.
RX   PubMed=16682172; DOI=10.1016/j.cellsig.2006.03.012;
RA   Vaillancourt M., Levasseur S., Tremblay M.-L., Marois L.,
RA   Rollet-Labelle E., Naccache P.H.;
RT   "The Src homology 2-containing inositol 5-phosphatase 1 (SHIP1) is
RT   involved in CD32a signaling in human neutrophils.";
RL   Cell. Signal. 18:2022-2032(2006).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-960; THR-963 AND
RP   SER-971, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   STRUCTURE BY NMR OF 1-112.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human SHIP SH2 domain.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [15]
RP   VARIANT GLU-685.
RX   PubMed=12529653; DOI=10.1038/sj.leu.2402725;
RA   Luo J.-M., Yoshida H., Komura S., Ohishi N., Pan L., Shigeno K.,
RA   Hanamura I., Miura K., Iida S., Ueda R., Naoe T., Akao Y., Ohno R.,
RA   Ohnishi K.;
RT   "Possible dominant-negative mutation of the SHIP gene in acute myeloid
RT   leukemia.";
RL   Leukemia 17:1-8(2003).
CC   -!- FUNCTION: Phosphatidylinositol (PtdIns) phosphatase that
CC       specifically hydrolyzes the 5-phosphate of phosphatidylinositol-
CC       3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2,
CC       thereby negatively regulating the PI3K (phosphoinositide 3-kinase)
CC       pathways. Acts as a negative regulator of B-cell antigen receptor
CC       signaling. Mediates signaling from the FC-gamma-RIIB receptor
CC       (FCGR2B), playing a central role in terminating signal
CC       transduction from activating immune/hematopoietic cell receptor
CC       systems. Acts as a negative regulator of myeloid cell
CC       proliferation/survival and chemotaxis, mast cell degranulation,
CC       immune cells homeostasis, integrin alpha-IIb/beta-3 signaling in
CC       platelets and JNK signaling in B-cells. Regulates proliferation of
CC       osteoclast precursors, macrophage programming, phagocytosis and
CC       activation and is required for endotoxin tolerance. Involved in
CC       the control of cell-cell junctions, CD32a signaling in neutrophils
CC       and modulation of EGF-induced phospholipase C activity. Key
CC       regulator of neutrophil migration, by governing the formation of
CC       the leading edge and polarization required for chemotaxis.
CC       Modulates FCGR3/CD16-mediated cytotoxicity in NK cells. Mediates
CC       the activin/TGF-beta-induced apoptosis through its Smad-dependent
CC       expression. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus
CC       affect the levels of the higher inositol polyphosphates like
CC       InsP6. {ECO:0000269|PubMed:12421919, ECO:0000269|PubMed:16682172}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 3,4,5-
CC       triphosphate + H(2)O = 1-phosphatidyl-1D-myo-inositol 3,4-
CC       diphosphate + phosphate. {ECO:0000269|PubMed:8723348,
CC       ECO:0000269|PubMed:8769125}.
CC   -!- ENZYME REGULATION: Activated upon translocation to the sites of
CC       synthesis of PtdIns(3,4,5)P3 in the membrane. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with tyrosine phosphorylated forms of SHC1,
CC       DOK1, DOK3, PTPN11/SHP-2, SLAMF1/CD150. Interacts with PTPN11 in
CC       response to IL-3. Interacts with receptors EPOR, MS4A2/FCER1B and
CC       FCER1G, FCGR2A, FCGR2B and FCGR3. Interacts with GRB2 and PLCG1.
CC       Interacts with tyrosine kinases SRC and TEC. Interacts with
CC       FCGR2A, leading to regulate gene expression during the phagocytic
CC       process. Interacts with c-Met/MET (By similarity). Interacts with
CC       MILR1 (tyrosine-phosphorylated). Can weakly interact (via NPXY
CC       motif 2) with DAB2 (via PID domain); the interaction is impaired
CC       by tyrosine phosphorylation of the NPXY motif (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9BZW8:CD244; NbExp=6; IntAct=EBI-1380477, EBI-1580565;
CC       P31994:FCGR2B; NbExp=3; IntAct=EBI-1380477, EBI-724784;
CC       O75525:KHDRBS3; NbExp=3; IntAct=EBI-1380477, EBI-722504;
CC       Q15323:KRT31; NbExp=3; IntAct=EBI-1380477, EBI-948001;
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-1380477, EBI-10171697;
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-1380477, EBI-10172290;
CC       P60411:KRTAP10-9; NbExp=3; IntAct=EBI-1380477, EBI-10172052;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-1380477, EBI-945833;
CC       Q96B97:SH3KBP1; NbExp=6; IntAct=EBI-1380477, EBI-346595;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10822173}.
CC       Cell membrane {ECO:0000250|UniProtKB:Q9ES52}; Peripheral membrane
CC       protein {ECO:0000250|UniProtKB:Q9ES52}. Membrane raft
CC       {ECO:0000250|UniProtKB:Q9ES52}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:Q9ES52}. Membrane
CC       {ECO:0000269|PubMed:10822173}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10822173}. Note=Translocates to the plasma
CC       membrane when activated, translocation is probably due to
CC       different mechanisms depending on the stimulus and cell type.
CC       Translocates from the cytoplasm to membrane ruffles in a
CC       FCGR3/CD16-dependent manner. Colocalizes with FC-gamma-RIIB
CC       receptor (FCGR2B) or FCGR3/CD16 at membrane ruffles. Tyrosine
CC       phosphorylation may also participate in membrane localization.
CC       {ECO:0000250|UniProtKB:Q9ES52}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q92835-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92835-2; Sequence=VSP_027978;
CC       Name=3; Synonyms=SIP-110;
CC         IsoId=Q92835-3; Sequence=VSP_027977, VSP_027979;
CC   -!- TISSUE SPECIFICITY: Specifically expressed in immune and
CC       hematopoietic cells. Expressed in bone marrow and blood cells.
CC       Levels vary considerably within this compartment. Present in at
CC       least 74% of immature CD34+ cells, whereas within the more mature
CC       population of CD33+ cells, it is present in only 10% of cells.
CC       Present in the majority of T-cells, while it is present in a
CC       minority of B-cells (at protein level).
CC       {ECO:0000269|PubMed:8769125, ECO:0000269|PubMed:8874179,
CC       ECO:0000269|PubMed:9058707, ECO:0000269|PubMed:9108392}.
CC   -!- DOMAIN: The SH2 domain interacts with tyrosine phosphorylated
CC       forms of proteins such as SHC1 or PTPN11/SHP-2. It competes with
CC       that of GRB2 for binding to phosphorylated SHC1 to inhibit the Ras
CC       pathway. It is also required for tyrosine phosphorylation (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated by the members of the SRC family
CC       after exposure to a diverse array of extracellular stimuli such as
CC       cytokines, growth factors, antibodies, chemokines, integrin
CC       ligands and hypertonic and oxidative stress. Phosphorylated upon
CC       IgG receptor FCGR2B-binding. {ECO:0000269|PubMed:10822173,
CC       ECO:0000269|PubMed:9108392}.
CC   -!- SIMILARITY: Belongs to the inositol 1,4,5-trisphosphate 5-
CC       phosphatase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50454.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98429; CAA67071.1; -; mRNA.
DR   EMBL; U57650; AAB53573.1; -; mRNA.
DR   EMBL; U50040; AAC50453.1; -; mRNA.
DR   EMBL; U50041; AAC50454.1; ALT_INIT; mRNA.
DR   EMBL; U84400; AAB49680.1; -; mRNA.
DR   EMBL; U53470; AAD00081.1; -; mRNA.
DR   EMBL; BC062985; AAH62985.1; -; mRNA.
DR   EMBL; BC099920; AAH99920.1; -; mRNA.
DR   EMBL; BC113580; AAI13581.1; -; mRNA.
DR   EMBL; BC113582; AAI13583.1; -; mRNA.
DR   CCDS; CCDS74672.1; -. [Q92835-1]
DR   CCDS; CCDS77543.1; -. [Q92835-2]
DR   PIR; JC4889; JC4889.
DR   RefSeq; NP_001017915.1; NM_001017915.2. [Q92835-1]
DR   RefSeq; NP_005532.2; NM_005541.4. [Q92835-2]
DR   UniGene; Hs.262886; -.
DR   UniGene; Hs.601911; -.
DR   PDB; 2YSX; NMR; -; A=1-112.
DR   PDBsum; 2YSX; -.
DR   ProteinModelPortal; Q92835; -.
DR   SMR; Q92835; -.
DR   BioGrid; 109847; 40.
DR   IntAct; Q92835; 27.
DR   MINT; MINT-123561; -.
DR   STRING; 9606.ENSP00000352575; -.
DR   ChEMBL; CHEMBL1781870; -.
DR   SwissLipids; SLP:000000951; -.
DR   DEPOD; Q92835; -.
DR   iPTMnet; Q92835; -.
DR   PhosphoSitePlus; Q92835; -.
DR   BioMuta; INPP5D; -.
DR   DMDM; 158564077; -.
DR   EPD; Q92835; -.
DR   MaxQB; Q92835; -.
DR   PaxDb; Q92835; -.
DR   PeptideAtlas; Q92835; -.
DR   PRIDE; Q92835; -.
DR   Ensembl; ENST00000359570; ENSP00000352575; ENSG00000168918. [Q92835-2]
DR   Ensembl; ENST00000445964; ENSP00000405338; ENSG00000168918. [Q92835-1]
DR   Ensembl; ENST00000629761; ENSP00000486669; ENSG00000281614. [Q92835-2]
DR   Ensembl; ENST00000630854; ENSP00000487191; ENSG00000281614. [Q92835-1]
DR   GeneID; 3635; -.
DR   KEGG; hsa:3635; -.
DR   UCSC; uc032ovq.2; human. [Q92835-1]
DR   CTD; 3635; -.
DR   DisGeNET; 3635; -.
DR   GeneCards; INPP5D; -.
DR   H-InvDB; HIX0057065; -.
DR   HGNC; HGNC:6079; INPP5D.
DR   HPA; CAB016300; -.
DR   HPA; HPA070455; -.
DR   MIM; 601582; gene.
DR   neXtProt; NX_Q92835; -.
DR   OpenTargets; ENSG00000168918; -.
DR   PharmGKB; PA29887; -.
DR   eggNOG; KOG0565; Eukaryota.
DR   eggNOG; COG5411; LUCA.
DR   GeneTree; ENSGT00760000119075; -.
DR   HOVERGEN; HBG106726; -.
DR   InParanoid; Q92835; -.
DR   KO; K03084; -.
DR   OMA; LTKPEMF; -.
DR   OrthoDB; EOG091G00P6; -.
DR   PhylomeDB; Q92835; -.
DR   TreeFam; TF323475; -.
DR   BioCyc; MetaCyc:HS09849-MONOMER; -.
DR   BRENDA; 3.1.3.86; 2681.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   SignaLink; Q92835; -.
DR   SIGNOR; Q92835; -.
DR   ChiTaRS; INPP5D; human.
DR   EvolutionaryTrace; Q92835; -.
DR   GeneWiki; INPP5D; -.
DR   GenomeRNAi; 3635; -.
DR   PRO; PR:Q92835; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000168918; -.
DR   CleanEx; HS_INPP5D; -.
DR   ExpressionAtlas; Q92835; baseline and differential.
DR   Genevisible; Q92835; HS.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0052659; F:inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0004445; F:inositol-polyphosphate 5-phosphatase activity; TAS:ProtInc.
DR   GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; TAS:Reactome.
DR   GO; GO:0034485; F:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0051425; F:PTB domain binding; IEA:Ensembl.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IEA:Ensembl.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0045779; P:negative regulation of bone resorption; IEA:Ensembl.
DR   GO; GO:0050777; P:negative regulation of immune response; IEA:Ensembl.
DR   GO; GO:0045409; P:negative regulation of interleukin-6 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045656; P:negative regulation of monocyte differentiation; IEA:Ensembl.
DR   GO; GO:0045659; P:negative regulation of neutrophil differentiation; IEA:Ensembl.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IEA:Ensembl.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; TAS:ProtInc.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IEA:InterPro.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.30.505.10; -; 1.
DR   Gene3D; 3.60.10.10; -; 1.
DR   InterPro; IPR005135; Endo/exonuclease/phosphatase.
DR   InterPro; IPR000300; IPPc.
DR   InterPro; IPR000980; SH2.
DR   Pfam; PF03372; Exo_endo_phos; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00128; IPPc; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56219; SSF56219; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Cell membrane;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Hydrolase; Immunity;
KW   Membrane; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   SH2 domain; SH3-binding.
FT   CHAIN         1   1189       Phosphatidylinositol 3,4,5-trisphosphate
FT                                5-phosphatase 1.
FT                                /FTId=PRO_0000302866.
FT   DOMAIN        5    101       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   REGION     1016   1030       Interaction with DAB2. {ECO:0000250}.
FT   MOTIF       124    129       SH3-binding 1.
FT   MOTIF       912    915       NPXY motif 1.
FT   MOTIF       969    974       SH3-binding 2.
FT   MOTIF      1019   1022       NPXY motif 2.
FT   MOTIF      1040   1051       SH3-binding 3.
FT   COMPBIAS    920   1148       Pro-rich.
FT   MOD_RES     243    243       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9ES52}.
FT   MOD_RES     915    915       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     934    934       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9ES52}.
FT   MOD_RES     944    944       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9ES52}.
FT   MOD_RES     960    960       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     963    963       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     971    971       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1022   1022       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9ES52}.
FT   VAR_SEQ       1    212       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:8723348}.
FT                                /FTId=VSP_027977.
FT   VAR_SEQ     117    117       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8769125,
FT                                ECO:0000303|PubMed:8874179}.
FT                                /FTId=VSP_027978.
FT   VAR_SEQ     213    222       TTLLCKELYG -> MFTLSPAPR (in isoform 3).
FT                                {ECO:0000303|PubMed:8723348}.
FT                                /FTId=VSP_027979.
FT   VARIANT     685    685       V -> E (in one patient with acute myeloid
FT                                leukemya; somatic mutation).
FT                                {ECO:0000269|PubMed:12529653}.
FT                                /FTId=VAR_034979.
FT   VARIANT    1169   1169       H -> Y (in dbSNP:rs9247).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8769125}.
FT                                /FTId=VAR_059358.
FT   CONFLICT     25     26       DG -> GT (in Ref. 4; AAB49680).
FT                                {ECO:0000305}.
FT   CONFLICT   1029   1029       P -> H (in Ref. 4; AAB49680).
FT                                {ECO:0000305}.
FT   STRAND        4      9       {ECO:0000244|PDB:2YSX}.
FT   HELIX        12     22       {ECO:0000244|PDB:2YSX}.
FT   STRAND       27     32       {ECO:0000244|PDB:2YSX}.
FT   STRAND       39     45       {ECO:0000244|PDB:2YSX}.
FT   STRAND       50     57       {ECO:0000244|PDB:2YSX}.
FT   STRAND       63     65       {ECO:0000244|PDB:2YSX}.
FT   STRAND       70     72       {ECO:0000244|PDB:2YSX}.
FT   STRAND       76     78       {ECO:0000244|PDB:2YSX}.
FT   HELIX        79     85       {ECO:0000244|PDB:2YSX}.
FT   STRAND       88     95       {ECO:0000244|PDB:2YSX}.
SQ   SEQUENCE   1189 AA;  133292 MW;  7958E91A64A4B68B CRC64;
     MVPCWNHGNI TRSKAEELLS RTGKDGSFLV RASESISRAY ALCVLYRNCV YTYRILPNED
     DKFTVQASEG VSMRFFTKLD QLIEFYKKEN MGLVTHLQYP VPLEEEDTGD DPEEDTVESV
     VSPPELPPRN IPLTASSCEA KEVPFSNENP RATETSRPSL SETLFQRLQS MDTSGLPEEH
     LKAIQDYLST QLAQDSEFVK TGSSSLPHLK KLTTLLCKEL YGEVIRTLPS LESLQRLFDQ
     QLSPGLRPRP QVPGEANPIN MVSKLSQLTS LLSSIEDKVK ALLHEGPESP HRPSLIPPVT
     FEVKAESLGI PQKMQLKVDV ESGKLIIKKS KDGSEDKFYS HKKILQLIKS QKFLNKLVIL
     VETEKEKILR KEYVFADSKK REGFCQLLQQ MKNKHSEQPE PDMITIFIGT WNMGNAPPPK
     KITSWFLSKG QGKTRDDSAD YIPHDIYVIG TQEDPLSEKE WLEILKHSLQ EITSVTFKTV
     AIHTLWNIRI VVLAKPEHEN RISHICTDNV KTGIANTLGN KGAVGVSFMF NGTSLGFVNS
     HLTSGSEKKL RRNQNYMNIL RFLALGDKKL SPFNITHRFT HLFWFGDLNY RVDLPTWEAE
     TIIQKIKQQQ YADLLSHDQL LTERREQKVF LHFEEEEITF APTYRFERLT RDKYAYTKQK
     ATGMKYNLPS WCDRVLWKSY PLVHVVCQSY GSTSDIMTSD HSPVFATFEA GVTSQFVSKN
     GPGTVDSQGQ IEFLRCYATL KTKSQTKFYL EFHSSCLESF VKSQEGENEE GSEGELVVKF
     GETLPKLKPI ISDPEYLLDQ HILISIKSSD SDESYGEGCI ALRLEATETQ LPIYTPLTHH
     GELTGHFQGE IKLQTSQGKT REKLYDFVKT ERDESSGPKT LKSLTSHDPM KQWEVTSRAP
     PCSGSSITEI INPNYMGVGP FGPPMPLHVK QTLSPDQQPT AWSYDQPPKD SPLGPCRGES
     PPTPPGQPPI SPKKFLPSTA NRGLPPRTQE SRPSDLGKNA GDTLPQEDLP LTKPEMFENP
     LYGSLSSFPK PAPRKDQESP KMPRKEPPPC PEPGILSPSI VLTKAQEADR GEGPGKQVPA
     PRLRSFTCSS SAEGRAAGGD KSQGKPKTPV SSQAPVPAKR PIKPSRSEIN QQTPPTPTPR
     PPLPVKSPAV LHLQHSKGRD YRDNTELPHH GKHRPEEGPP GPLGRTAMQ
//
